Torthaí cuardaigh - Akshita Gupta
- 1 - 3 toradh as 3 á dtaispeáint
-
1
Economic burden and cost-effectiveness of therapies for <i>Clostridiodes difficile</i> infection: a narrative review de réir Akshita Gupta, Ashwin N. Ananthakrishnan
Foilsithe / Cruthaithe 2021Revisão -
2
Therapies to modulate gut microbiota: Past, present and future de réir Akshita Gupta, Srishti Saha, Sahil Khanna
Foilsithe / Cruthaithe 2020Revisão -
3
Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments de réir Akshita Gupta, Angelina Konnova, Mathias Smet, Matilda Berkell, Alessia Savoldi, Matteo Morra, Vincent Van averbeke, Fien H. R. De Winter, Denise Peserico, Elisa Danese, An Hotterbeekx, Elda Righi, Pasquale De Nardo, Evelina Tacconelli, Surbhi Malhotra‐Kumar, Samir Kumar‐Singh
Foilsithe / Cruthaithe 2023Artigo
Uirlisí cuardaigh:
Ábhair a bhaineann le hábhar
Biology
Disease
Medicine
Antibiotics
Bacteria
Clostridium difficile
Diarrhea
Genetics
Immunology
Intensive care medicine
Internal medicine
Microbiology
2019-20 coronavirus outbreak
Adverse effect
Antibody
Bioinformatics
Burden of disease
Clinical trial
Clostridioides
Coronavirus disease 2019 (COVID-19)
Cost effectiveness
Disease burden
Dysbiosis
Economic growth
Economics
Fecal bacteriotherapy
Fidaxomicin
Gut flora
Gut–brain axis
Health care